Inducible nitric oxide synthase inhibitors prolonged the survival of skin xenografts through selective down-regulation of pro-inflammatory cytokine and CC-chemokine expressions

Transplant Immunology

Volumn 12, Issue 1, 2003, Pages 63-72

  Kim, Jae Young ^a   Kim, Donghee ^a   Lee, Eun Mi ^a   Choi, Inho ^a   Park, Chung Gyu ^a,b   Kim, Kil Soo ^b   Ha, Jongwon ^a,b   Kim, Sang Joon ^a,b   Yang, Jaeseok ^b   Kim, Yon Su ^b   Han, Jin Suk ^b   Kim, Suhnggwon ^b   Lee, Jung Sang ^b   Ahn, Curie ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Cytokines; Inducible nitric oxide synthase inhibitors; Skin xenografts

Indexed keywords

AMINOGUANIDINE; CD11B ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERFERON GAMMA INDUCIBLE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; MONOKINE INDUCED BY INTERFERON GAMMA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; RANTES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VANILMANDELIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFECT; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INHIBITION KINETICS; LONG TERM CARE; LYMPHOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SKIN GRAFT; SKIN TRANSPLANTATION; XENOGRAFT;

EID: 0142182173     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(03)00013-3     Document Type: Article

References (43)

1. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142.
2. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992;6:3051-3064.
3. DeGroote MA, Fang FC. Antimicrobial properties of nitric oxide. In: Fang FC, editor. Nitric Oxide and Infection. 1999. p.231-261.
4. Nathan C, Shiloh MU. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci USA 2000;97:8841-8848.
5. Bogdan C. The function of nitric oxide in the immune system. In: Meyer B, editor. Handbook of Experimental Pharmacology. Volume: Nitric Oxide. 2000. p. 443-492.
6. Pervin S, Singh R, Chaudhuri G. Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): Potential role of cyclin D1. Proc Natl Acad Sci USA 2001;98:3583-3588.
7. Bauer PM, Buga GM, Fukuto JM, Pegg AE, Ignarro LJ. Nitric oxide inhibits ornithine decarboxylase via S-nitrosylation of cysteine 360 in the active site of the enzyme. J Biol Chem 2001;276(37):34458-34464.
8. Bobe P, Benihoud K, Grandjon D, Opolon P, Pritchard LL, Huchet R. Nitric oxide mediation of active immunosuppression associated with graft-versus-host reaction. Blood 1999;94(3):1028-1037.
9. Kahn DA, Archer DC, Gold DP, Kelly CJ. Adjuvant immunotherapy is dependent on inducible nitric oxide synthase. J Exp Med 2001;193(11):1261-1268.
10. Allione A, Bernabei P, Bosticardo M, Ariotti S, Forni G, Novelli F. Nitric oxide suppresses human T lymphocyte proliferation through IFN-gamma-dependent and IFN-gamma-independent induction of apoptosis. J Immunol 1999;163(8):4182-4191.
11. Kolb H, Kolb-Bachofen V. Nitric oxide in autoimmune disease: Cytotoxic or regulatory mediator. Immunol Today 1998;19:556-561.
12. Pfeilschiffer J, Eberhardt W, Beck KF. Regulation of gene expression by nitric oxide. Pflugers Archiv Eur J Physiol 2001;442:479-486.
13. Marshall HE, Merchant K, Stamler JS. Nitrosation and oxidation in the regulation of gene expression. FASEB J 2000;14:1889-1900.
14. Berendji D, et al. Zinc finger transcription factor as molecular target for nitric oxide-mediated immunosuppression: Inhibition of IL-2 gene expression in lymphocytes. Mol Med 1999;5(11):721-730.
15. Wang S, Yan L, Wesley RA, Danner RL. A Sp1 binding site of the tumor necrosis factor α promotor functions as a nitric oxide response element. J Biol Chem 1999;274:33190-33193.
16. Vodovotz Y, et al. Regulation of transforming growth factor β1 by nitric oxide. Cancer Res 1999;59:2142-2149.
17. Bauer PM, Jung T, Tsikas D, Stichtenoth DO, Frolich JC, Neumann C. Nitric oxide inhibits the secretion of T-helper 1- and T-helper 2-associated cytokines in activated human T cells. Immunology 1997;90:205-211.
18. Niedbala W, Wei XQ, Piedrafita D, Xu D, Liew FY. Effects of nitric oxide on the induction and differentiation of Th1 cells. Eur J Immunol 1999;29:2498-2505.
19. Langrehr JM, Dull KE, Ochoa JB, et al. Evidence that nitric oxide production by in vivo allosensitized cells inhibits the development of allospecific CTL. Transplantation 1992;53:632-640.
20. Tanak S, Kamiike W, Ito T, et al. Generation of nitric oxide as a rejection marker in rat pancreas transplantation. Transplantation 1995;60:713-717.
21. Lancaster JR Jr., Langrehr JM, Bergonia HA, et al. EPR detection of heme and nonheme iron-containing protein nitrosylation by nitric oxide during rejection of rat heart allograft. J Biol Chem 1992;267:10994-10998.
22. Cattell B, Smith J, Jansen A, Riveros-Moreno V, Moncada S. Localization of inducible nitric oxide synthase in acute renal allograft rejection in the rat. Transplantation 1994;58:1399-1402.
23. Kuo PC, Alfrey EJ, Krieger MR, et al. Differential localization of allograft nitric oxide synthase: Comparison of liver and heart transplantation in the rat model. Immunology 1996;87:647-653.
24. Yang X, Chowdhury N, Cal B, et al. Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest 1994;94:714-721.
25. Winlaw DS, Schyvens CG, Smythe GA, et al. Urinary nitrate excretion is a noninvasive indication of acute cardiac allograft rejection and nitric oxide production in the rat. Transplantation 1994;58:1031-1036.
26. Devlin J, Palmer RMJ, Gonde CE, et al. Nitric oxide generation: A predictive parameter of acute allograft rejection. Transplantation 1994;58:592-595.
27. Russell ME, Wallace AF, Wyner LR, Newell JB, Karnovsky MJ. Upregulation and modulation of inducible nitric oxide synthase in rat cardiac allografts with chronic rejection and transplant arteriosclerosis. Circulation 1995;92:457-464.
28. Akyurek LM, Fellstrom BC, Yan Z-Q, Hansson GK, Funa K, Larsson E. Inducible and endothelial nitric oxide synthase expression during development of transplant arteriosclerosis in rat aortic grafts. Am J Pathol 1996;149:1981-1990.
29. Shears LL II, Kawaharada N, Tzeng E, et al. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest 1997;100:2035-2042.
30. Worrall NK, Misko TP, Sullivan PM, Hui J-J, Ferguson TB Jr. Inhibition of inducible nitric oxide synthase attenuates established acute cardiac allograft rejection. Ann Thorc Surg 1996;62:378-385.
31. Yang X, Szabolcs M, Minanov O, et al. CNI-1493 prolongs survival and reduces myocyte loss, apoptosis, and inflammation during rat cardiac allograft rejection. J Cardiovasc Pharmacol 1998;32(1):146-155.
32. Winlaw DS, Schyvens CG, Smythe GA, et al. Selective inhibition of nitric oxide production during cardiac allograft rejection causes a small increase in graft survival. Transplantation 1995;60:77-82.
33. Cai B, Roy DK, Sciacca R, Michler RE, Cannon PJ. Effects of immunosuppressive therapy on expression of inducible nitric oxide synthase (iNOS) during cardiac allograft rejection. Int J Cardiol 1995;50:243-251.
34. Rosenberg AS. In vivo assays for mouse lymphocyte function. Skin allograft rejection. Curr Protocols Immunol 1991;1:4.4.1-1.4.9.
35. Vos IHC, et al. Inhibition of inducible nitric oxide synthase improves graft function and reduces tubulointerstitial injury in renal allograft rejection. Eur J Pharmacol 2000;391:31-38.
36. Nathan C. Inducible nitric oxide synthase: What difference does it make. J Clin Invest 1997;100:2417-2423.
37. Hibbs JB Jr., Lancaster JR Jr.. EPR demonstration of iron-nitrosyl complex formation by cytotoxic activated macrophages. Proc Natl Acad Sci USA 1990;87:1223-1227.
38. Heeringa P, van Goor H, Moshage H, et al. Expression of iNOS, eNOS, and peroxynitrite-modified proteins in experimental anti-myeloperoxydase associated crescentic glomerulonephritis. Kidney Int 1998;53:382-393.
39. Balligand JL, Cannon PJ. Nitric oxide synthase and cardiac muscle: Autocrine and paracrine influences. Arterioscler Thromb Vasc Biol 1997;17:1846-1858.
40. Villalta F, Zhang Y, Bibb KE, Kappes JC, Lima MF. The cysteine-cysteine family of chemokines RANTES, MIP-1alpha, and MIP-1beta induce trypanocidal activity in human macrophages via nitric oxide. Infect Immun 1998; 66(10):24690-24695.
41. Mannon RB, Robert K, Ruiz P, Laubach V, Coffman TM. Inducible nitric oxide synthase promotes cytokine expression in cardiac allografts but is not required for efficient rejection. J Heart Lung Transplant 1999;18:819-827.
42. Mach F, Sauty A, Iarossi AS, et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999;104(8):1041-1050.
43. Trifilieff A, Fujitani Y, Mentz F, Dugas B, Fuentess M, Bertrand C. Inducible nitric oxide synthase inhibitors suppress airway inflammation in mice through down-regulation of chemokine expression. J Immunol 2000;165(3):1526-1533.